Novel (Atypical) Antidepressants

Heidi R. Bruty, Graham J. Emslie, Paul E Croarkin

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

While the selective serotonin-reuptake inhibitors (SSRIs) are the first line treatment for juvenile depression and anxiety disorders, other novel antidepressants not chemically related to the SSRIs have also been prescribed to children and adolescents for unlabeled (non-FDA-approved) indications. These medications include bupropion, (Wellbutrin™), duloxetine Hydrochloride (Cymbalta™), mirtazapine (Remeron ™), trazodone (Desyrel™), venlafaxine (Effexor ™) and desvenlafaxine (Pristiq™). Their psychopharmacological profile and relevant pediatric studies are summarized in this chapter. Alternative or complimentary treatments (e.g. St. John's Wort, Omega-3 fatty acids, thyroid hormones, and S-Adenosyl Methionine (SAMe)) are also reviewed.

Original languageEnglish (US)
Title of host publicationPharmacotherapy of Child and Adolescent Psychiatric Disorders: Third Edition
PublisherJohn Wiley and Sons
Pages155-179
Number of pages25
ISBN (Print)9780470973769
DOIs
StatePublished - Feb 17 2012
Externally publishedYes

    Fingerprint

Keywords

  • Antidepressants
  • Anxiety
  • Depression
  • Pediatric Psychopharmacology

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Bruty, H. R., Emslie, G. J., & Croarkin, P. E. (2012). Novel (Atypical) Antidepressants. In Pharmacotherapy of Child and Adolescent Psychiatric Disorders: Third Edition (pp. 155-179). John Wiley and Sons. https://doi.org/10.1002/9781119958338.ch9